ABM-1310

DRUG3 trials

Sponsors

ABM Therapeutics Corporation, ABM Therapeutics Shanghai Company Limited

Conditions

Advanced Solid TumorBRAF V600 MutationPrimary Malignant Brain Tumor

Phase 1

Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

TerminatedNCT04190628

ABM Therapeutics CorporationAdvanced Solid Tumor, BRAF V600 Mutation

Start: 2020-06-16End: 2024-04-05Updated: 2024-05-21

A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors

TerminatedNCT05501912

ABM Therapeutics Shanghai Company LimitedAdvanced Solid Tumor, BRAF V600 Mutation

Start: 2022-09-01End: 2024-06-17Updated: 2024-11-29

A Study of ABM-1310 in Patients With BRAF V600-Mutant Relapsed and Drug Resistant Primary Malignant Brain Tumors

TerminatedNCT05892653

ABM Therapeutics Shanghai Company LimitedPrimary Malignant Brain Tumor

Start: 2023-06-30End: 2024-08-27Updated: 2024-11-29

Related Papers

CTNI-11. A PHASE 1 OPEN-LABEL STUDY OF BRAF INHIBITOR ABM-1310 IN PATIENTS (PTS) WITH RECURRENT BRAF V600-MUTATED PRIMARY CNS TUMORS

Neuro-Oncology2024-11-01

Interim analysis of ABM-1310, a blood-brain barrier-penetrant BRAF inhibitor, in patients with <i>BRAF V600</i>-mutated solid tumors.

Journal of Clinical Oncology2024-06-015 citations

A phase 1, multicenter, open-label study of a new BRAF inhibitor ABM-1310 in adult patients (pts) with <i>BRAFv600</i>-mutated solid tumors.

Journal of Clinical Oncology2023-06-018 citations